Concord Biotech Limited

NSEI:CONCORDBIO Stok Raporu

Piyasa değeri: ₹189.9b

Concord Biotech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 6/6

Concord Biotech has been growing earnings at an average annual rate of 13.1%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 19.7% per year. Concord Biotech's return on equity is 20.5%, and it has net margins of 30.2%.

Anahtar bilgiler

13.1%

Kazanç büyüme oranı

13.1%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi17.5%
Gelir büyüme oranı19.7%
Özkaynak getirisi20.5%
Net Marj30.2%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?

Sep 15
Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?

Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing

Jul 23
Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing

Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?

Feb 14
Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?

Gelir ve Gider Dağılımı

Concord Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NSEI:CONCORDBIO Gelir, gider ve kazançlar (INR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2410,3793,1321,2650
31 Mar 2410,1693,0811,2310
31 Dec 239,7063,0461,1780
30 Sep 239,7043,0441,1470
30 Jun 238,6702,4531,1340
31 Mar 238,5322,4011,1030
31 Mar 227,1291,7499570
31 Mar 216,1692,3497000
31 Mar 205,1231,6916240

Kaliteli Kazançlar: CONCORDBIO has high quality earnings.

Büyüyen Kar Marjı: CONCORDBIO's current net profit margins (30.2%) are higher than last year (28.3%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CONCORDBIO's earnings have grown by 13.1% per year over the past 5 years.

Büyüme Hızlandırma: CONCORDBIO's earnings growth over the past year (27.7%) exceeds its 5-year average (13.1% per year).

Kazançlar vs. Sektör: CONCORDBIO earnings growth over the past year (27.7%) exceeded the Pharmaceuticals industry 19.1%.


Özkaynak Getirisi

Yüksek ROE: CONCORDBIO's Return on Equity (20.5%) is considered high.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin